ESR1 and prostate cancer: In PC-3, an androgen-insensitive prostate cancer cell line not expressing AR but having ERα (Lau et al, 2000), RES treatment also produced a concentration-dependent reduction in ERα with a maximum effect at 100–150 μM (Figure 1D).